Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.
Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.
Heart. 2019 Jul;105(14):1096-1102. doi: 10.1136/heartjnl-2018-314076. Epub 2019 Feb 21.
The aim of this study is to evaluate the long-term risk of cardiac death and sudden cardiac death (SCD) and/or sustained ventricular arrhythmias (SVAs) in patients with coronary chronic total occlusions (CTO) revascularised versus those with CTO not revascularised by percutaneous coronary intervention (PCI).
From a cohort of 1357 CTO-PCI patients, 1162 patients who underwent CTO PCI attempt were included in this long-term analysis: 837 patients were revascularised by PCI (CTO-R group) and 325 were not revascularised (CTO-NR group). Primary adverse endpoint was the incidence of cardiac death; secondary endpoint was the cumulative incidence of SCD/SVAs.
Up to 12-year follow-up (median 6 year), compared with CTO-R patients, those with CTO-NR had significantly higher rate of cardiac death (13%[43/325]vs6%[48/837]; p<0.001) and SCD/SVAs (7.5%[24/325]vs2.5%[20/837]; p<0.001). The risk of cardiac death and SCD/SVAs was mainly driven by the subgroup of infarct-related artery (IRA) CTO patients and was significantly higher only in IRA CTO-NR patients (18%vs7%, p<0.001, 14%vs5%, p=0.001; IRA CTO-NR vs IRA CTO-R, respectively). At multivariable Cox hazards regression analysis, CTO-NR remains one of the strongest independent predictors of higher risk of cardiac death and of SCD/SVAs in the overall population and in IRA CTO patients.
At long-term follow-up, patients with CTO not revascularised by PCI had worse outcomes compared with those with CTO revascularised, with >2-fold risk of cardiac death and threefold risk of SCD/SVAs. The presence of an infarct-related artery (IRA CTO) not revascularised identified the category of patients with the highest rate of adverse events .
本研究旨在评估经皮冠状动脉介入治疗(PCI)血运重建与未血运重建的冠状动脉慢性完全闭塞(CTO)患者的心脏性死亡和心源性猝死(SCD)及/或持续性室性心律失常(SVA)的长期风险。
从 1357 例 CTO-PCI 患者中,纳入了 1162 例接受 CTO-PCI 尝试的患者进行这项长期分析:837 例患者经 PCI 血运重建(CTO-R 组),325 例患者未血运重建(CTO-NR 组)。主要不良终点为心脏性死亡发生率;次要终点为 SCD/SVA 的累积发生率。
随访时间长达 12 年(中位随访时间 6 年),与 CTO-R 患者相比,CTO-NR 患者的心脏性死亡(13%[43/325]vs6%[48/837];p<0.001)和 SCD/SVA(7.5%[24/325]vs2.5%[20/837];p<0.001)发生率显著更高。心脏性死亡和 SCD/SVA 的风险主要由梗死相关动脉(IRA)CTO 患者亚组驱动,仅在 IRA CTO-NR 患者中显著更高(18%vs7%,p<0.001,14%vs5%,p=0.001;IRA CTO-NR 与 IRA CTO-R 相比)。多变量 Cox 风险回归分析显示,CTO-NR 仍然是总体人群和 IRA CTO 患者中更高心脏性死亡和 SCD/SVA 风险的最强独立预测因素之一。
在长期随访中,与 CTO 经 PCI 血运重建的患者相比,未血运重建的 CTO 患者的预后更差,心脏性死亡和 SCD/SVA 的风险增加 2 倍以上。未血运重建的梗死相关动脉(IRA CTO)的存在确定了不良事件发生率最高的患者类别。